Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

Dr Bertrand Tombal - Catholic University of Louvain, Belgium
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer ( Dr Bertrand Tombal - Catholic University of Louvain, Belgium )
25 Feb 2013

Effect of therapeutic anticoagulation on overall survival in men receiving docetaxel for mCRPC

Dr Caroline Pratz - Kimmel Cancer Center, Johns Hopkins University, Baltimore
Effect of therapeutic anticoagulation on overall survival in men receiving docetaxel for mCRPC ( Dr Caroline Pratz - Kimmel Cancer Center, Johns Hopkins University, Baltimore )
25 Feb 2013

New agents and mTOR inhibitors

Dr David Sabatini – Whitehead Institute, Boston, USA
New agents and mTOR inhibitors ( Dr David Sabatini – Whitehead Institute, Boston, USA )
7 Dec 2012

New genetic sub-types of breast, ovarian and prostate cancer

Dr Paul Pharoah – University of Cambridge, UK
New genetic sub-types of breast, ovarian and prostate cancer ( Dr Paul Pharoah – University of Cambridge, UK )
14 Nov 2012

Advances in the treatment of prostate cancer

Prof Malcolm Mason – Cardiff University, UK
Advances in the treatment of prostate cancer ( Prof Malcolm Mason – Cardiff University, UK )
14 Nov 2012

Recent evidence to support the use of aspirin in the treatment of cancer

Dr Ruth Langley – Medical Research Council, London, UK
Recent evidence to support the use of aspirin in the treatment of cancer ( Dr Ruth Langley – Medical Research Council, London, UK )
1 Nov 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 1

Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
15 Oct 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 3

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 3 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 2

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012

Genes, chromosomes and the treatment of bladder cancer

Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA
Genes, chromosomes and the treatment of bladder cancer ( Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Oct 2012

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012

Personalised cancer medicine and research: Today’s best practice

Prof José Baselga - Massachusetts General Hospital, Boston, USA
Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )
5 Oct 2012